Journal of the American Heart Association · 2026
Development and Validation of a Machine Learning Model to Predict Oral Anticoagulant Use in Stroke From Prothrombin Time-International Normalized Ratio and Activated Partial Thromboplastin Time.
СтатьяВалидационное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujiwara Gaku, Nagakane Yoshinari, Murakami Nobukuni, Suehiro Eiichi, Hashimoto Naoya, Yoshimura Sohei, Toyoda Kazunori, Okada Yohei
Аннотация
BACKGROUND: Timely recognition of oral anticoagulant use is critical in acute stroke but is often hampered by impaired consciousness and unavailable medication history. We investigated whether routinely available coagulation tests, prothrombin time-international normalized ratio and activated partial thromboplastin time, paired with machine learning can identify anticoagulant exposure at presentation.
METHODS: We performed a multicenter diagnostic modeling study using the Japan Stroke Data Bank. Adults with ischemic or hemorrhagic stroke admitted in 2016 to 2021 comprised the derivation cohort; those in 2022 formed a temporally distinct validation cohort. Three models (random forest, extreme gradient boosting, and neural network) used prothrombin time-international normalized ratio and activated partial thromboplastin time as predictors to classify anticoagulant status: vitamin K antagonist, direct oral anticoagulant, or none. Discrimination (area under the receiver operating characteristic curve and area under the precision-recall curve), calibration, and decision curve analysis were assessed. Model outputs were implemented as bedside probability heat maps.
RESULTS: Among 30 767 patients (derivation n=24 857; validation n=5910), vitamin K antagonist/direct oral anticoagulant use was 4.5%/8.2% in derivation and 2.8%/9.5% in validation. In the validation cohort, the neural network yielded the best performance: area under the receiver operating characteristic curve, 0.933 (95% CI, 0.908-0.955) and area under the precision-recall curve, 0.52 (95% CI, 0.44-0.61) for vitamin K antagonist; area under the receiver operating characteristic curve, 0.841 (95% CI, 0.822-0.858) and area under the precision-recall curve, 0.39 (95% CI, 0.35-0.43) for direct oral anticoagulant, with preserved calibration and highest net benefit across clinically relevant thresholds. Heat maps summarized class probabilities over the prothrombin time-international normalized ratio×activated partial thromboplastin time space to support rapid inference.
CONCLUSIONS: A simple machine learning model using only prothrombin time-international normalized ratio and activated partial thromboplastin time classified vitamin K antagonist and direct oral anticoagulant exposure with high accuracy and practical clinical utility. This tool assists emergency decision-making when medication history is unknown, supporting the safety and timeliness of acute stroke care.
METHODS: We performed a multicenter diagnostic modeling study using the Japan Stroke Data Bank. Adults with ischemic or hemorrhagic stroke admitted in 2016 to 2021 comprised the derivation cohort; those in 2022 formed a temporally distinct validation cohort. Three models (random forest, extreme gradient boosting, and neural network) used prothrombin time-international normalized ratio and activated partial thromboplastin time as predictors to classify anticoagulant status: vitamin K antagonist, direct oral anticoagulant, or none. Discrimination (area under the receiver operating characteristic curve and area under the precision-recall curve), calibration, and decision curve analysis were assessed. Model outputs were implemented as bedside probability heat maps.
RESULTS: Among 30 767 patients (derivation n=24 857; validation n=5910), vitamin K antagonist/direct oral anticoagulant use was 4.5%/8.2% in derivation and 2.8%/9.5% in validation. In the validation cohort, the neural network yielded the best performance: area under the receiver operating characteristic curve, 0.933 (95% CI, 0.908-0.955) and area under the precision-recall curve, 0.52 (95% CI, 0.44-0.61) for vitamin K antagonist; area under the receiver operating characteristic curve, 0.841 (95% CI, 0.822-0.858) and area under the precision-recall curve, 0.39 (95% CI, 0.35-0.43) for direct oral anticoagulant, with preserved calibration and highest net benefit across clinically relevant thresholds. Heat maps summarized class probabilities over the prothrombin time-international normalized ratio×activated partial thromboplastin time space to support rapid inference.
CONCLUSIONS: A simple machine learning model using only prothrombin time-international normalized ratio and activated partial thromboplastin time classified vitamin K antagonist and direct oral anticoagulant exposure with high accuracy and practical clinical utility. This tool assists emergency decision-making when medication history is unknown, supporting the safety and timeliness of acute stroke care.
Предметные рубрики MeSH
AgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralAnticoagulantsBoosting Machine Learning AlgorithmsClassification AlgorithmsHemorrhagic StrokeInternational Normalized RatioIschemic StrokeJapanMachine LearningPartial Thromboplastin TimePredictive Learning ModelsPredictive Value of TestsProthrombin TimeRandom ForestReproducibility of ResultsStroke